FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4249209754> ?p ?o ?g. }

• W4249209754 abstract "Background Mucopolysaccharidosis type I can be classified as three clinical sub‐types; Hurler syndrome, Hurler‐Scheie syndrome and Scheie syndrome, with the scale of severity being such that Hurler syndrome is the most severe and Scheie syndrome the least severe. It is a rare, autosomal recessive disorder caused by a deficiency of alpha‐L‐iduronidase. Deficiency of this enzyme results in the accumulation of glycosaminoglycans within the tissues. The clinical manifestations are facial dysmorphism, hepatosplenomegaly, upper airway obstruction, skeletal deformity and cardiomyopathy. If Hurler syndrome is left untreated, death ensues by adolescence. There are more attenuated variants termed Hurler‐Scheie or Scheie syndrome, with those affected potentially not presenting until adulthood. Enzyme replacement therapy has been used for a number of years in the treatment of Hurler syndrome, although the current gold standard would be a haemopoietic stem cell transplant in those diagnosed by 2.5 years of age. Objectives To evaluate the effectiveness and safety of treating mucopolysaccharidosis type I with laronidase enzyme replacement therapy as compared to placebo. Search methods We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Inborn Errors of Metabolism Trials Register, MEDLINE via OVID and EMBASE. Date of most recent search: 08 February 2013. Selection criteria Randomised and quasi‐randomised controlled trials of laronidase enzyme replacement therapy compared to placebo. Data collection and analysis Two authors independently screened the identified trials. The authors then appraised and extracted data. Main results One study of 45 patients met the inclusion criteria. This double‐blind, placebo‐controlled, randomised, multinational trial looked at laronidase at a dose of 0.58 mg/kg/week versus placebo in patients with mucopolysaccharidosis type I. All primary outcomes listed in this review were studied in this trial. The laronidase group achieved statistically significant improvements in per cent predicted forced vital capacity compared to placebo, MD 5.60 (95% confidence intervals 1.24 to 9.96) and in the six‐minute‐walk test (mean improvement of 38.1 metres in the laronidase group; P = 0.66, when using a prospectively planned analysis of covariance). The levels of urinary glycoaminoglycans were also significantly reduced. In addition, there were improvements in hepatomegaly, sleep apnoea and hypopnoea. Laronidase antibodies were detected in nearly all patients in the treatment group with no apparent clinical effect and titres were reducing by the end of the study. Infusion‐related adverse reactions occurred in both groups but all were mild and none necessitated medical intervention or infusion cessation. Authors' conclusions The current evidence demonstrates that laronidase is effective when compared to placebo in the treatment of mucopolysaccharidosis type I. The included trial was comprehensive and of good quality, although there were few participants. The trial included all of the key outcome measures we wished to look at. It demonstrated that laronidase is efficacious in relation to reducing biochemical parameters (reduced urine glycosaminoglycan excretion) and improved functional capacity as assessed by forced vital capacity and the six‐minute‐walk test. In addition glycosaminoglycan storage was reduced as ascertained by a reduction in liver volume. Laronidase appeared to be safe and, while antibodies were generated, these titres were reducing by the end of the study. More studies are required to determine long‐term effectiveness and safety and to assess the impact upon quality of life. Enzyme replacement therapy with laronidase can be used pre‐ and peri‐haemopoietic stem cell transplant, which is now the gold standard treatment in those patients diagnosed under 2.5 years of age." @default.
• W4249209754 created "2022-05-12" @default.
• W4249209754 creator A5011860876 @default.
• W4249209754 creator A5015169555 @default.
• W4249209754 creator A5058641127 @default.
• W4249209754 date "2013-09-26" @default.
• W4249209754 modified "2023-10-17" @default.
• W4249209754 title "Enzyme replacement therapy with laronidase (Aldurazyme^®) for treating mucopolysaccharidosis type I" @default.
• W4249209754 cites W1968758382 @default.
• W4249209754 cites W1985193566 @default.
• W4249209754 cites W1990892818 @default.
• W4249209754 cites W2022570021 @default.
• W4249209754 cites W2033501358 @default.
• W4249209754 cites W2043754477 @default.
• W4249209754 cites W2059192486 @default.
• W4249209754 cites W2085884984 @default.
• W4249209754 cites W2093722439 @default.
• W4249209754 cites W2128772588 @default.
• W4249209754 cites W2136255603 @default.
• W4249209754 cites W2145253443 @default.
• W4249209754 cites W2161236662 @default.
• W4249209754 cites W2312413018 @default.
• W4249209754 cites W2604596332 @default.
• W4249209754 doi "https://doi.org/10.1002/14651858.cd009354.pub2" @default.
• W4249209754 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24085657" @default.
• W4249209754 hasPublicationYear "2013" @default.
• W4249209754 type Work @default.
• W4249209754 citedByCount "17" @default.
• W4249209754 countsByYear W42492097542015 @default.
• W4249209754 countsByYear W42492097542016 @default.
• W4249209754 countsByYear W42492097542017 @default.
• W4249209754 countsByYear W42492097542019 @default.
• W4249209754 countsByYear W42492097542021 @default.
• W4249209754 countsByYear W42492097542022 @default.
• W4249209754 crossrefType "reference-entry" @default.
• W4249209754 hasAuthorship W4249209754A5011860876 @default.
• W4249209754 hasAuthorship W4249209754A5015169555 @default.
• W4249209754 hasAuthorship W4249209754A5058641127 @default.
• W4249209754 hasBestOaLocation W42492097541 @default.
• W4249209754 hasConcept C126322002 @default.
• W4249209754 hasConcept C141071460 @default.
• W4249209754 hasConcept C142724271 @default.
• W4249209754 hasConcept C187212893 @default.
• W4249209754 hasConcept C204787440 @default.
• W4249209754 hasConcept C27081682 @default.
• W4249209754 hasConcept C2777636572 @default.
• W4249209754 hasConcept C2779134260 @default.
• W4249209754 hasConcept C2779416428 @default.
• W4249209754 hasConcept C2779969927 @default.
• W4249209754 hasConcept C2910509766 @default.
• W4249209754 hasConcept C2910727661 @default.
• W4249209754 hasConcept C535046627 @default.
• W4249209754 hasConcept C71924100 @default.
• W4249209754 hasConceptScore W4249209754C126322002 @default.
• W4249209754 hasConceptScore W4249209754C141071460 @default.
• W4249209754 hasConceptScore W4249209754C142724271 @default.
• W4249209754 hasConceptScore W4249209754C187212893 @default.
• W4249209754 hasConceptScore W4249209754C204787440 @default.
• W4249209754 hasConceptScore W4249209754C27081682 @default.
• W4249209754 hasConceptScore W4249209754C2777636572 @default.
• W4249209754 hasConceptScore W4249209754C2779134260 @default.
• W4249209754 hasConceptScore W4249209754C2779416428 @default.
• W4249209754 hasConceptScore W4249209754C2779969927 @default.
• W4249209754 hasConceptScore W4249209754C2910509766 @default.
• W4249209754 hasConceptScore W4249209754C2910727661 @default.
• W4249209754 hasConceptScore W4249209754C535046627 @default.
• W4249209754 hasConceptScore W4249209754C71924100 @default.
• W4249209754 hasLocation W42492097541 @default.
• W4249209754 hasLocation W42492097542 @default.
• W4249209754 hasOpenAccess W4249209754 @default.
• W4249209754 hasPrimaryLocation W42492097541 @default.
• W4249209754 hasRelatedWork W1963911681 @default.
• W4249209754 hasRelatedWork W1990243713 @default.
• W4249209754 hasRelatedWork W2015597043 @default.
• W4249209754 hasRelatedWork W2029085773 @default.
• W4249209754 hasRelatedWork W2106564695 @default.
• W4249209754 hasRelatedWork W2294727991 @default.
• W4249209754 hasRelatedWork W3128228216 @default.
• W4249209754 hasRelatedWork W4224111136 @default.
• W4249209754 hasRelatedWork W4308256952 @default.
• W4249209754 hasRelatedWork W2225131080 @default.
• W4249209754 isParatext "false" @default.
• W4249209754 isRetracted "false" @default.
• W4249209754 workType "reference-entry" @default.